Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMMRYEK)

Drug Name
MPSK3169A Drug Info
Synonyms RG7652
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 2 [1]
Metabolic disorder 5C50-5D2Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMMRYEK

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PCSK9 messenger RNA (PCSK9 mRNA) TTNIZ2B PCSK9_HUMAN Modulator [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cardiovascular disease
ICD Disease Classification BA00-BE2Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PCSK9 messenger RNA (PCSK9 mRNA) DTT PCSK9 4.82E-02 -0.07 -0.3
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01609140) A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease. U.S. National Institutes of Health.
2 GW24-e2907 ffects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study. Heart 2013;99:A153.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388).